PATENT CLAIM ANALYSIS

Application Number: 15780964
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["424", "401000"]

Abstract:
The invention relates to a compatible solute or a solute mixture as well as to a composition comprising at least one solute or one solute mixture for use in the prevention or treatment of barrier malfunctions of epithelial tissues associated with at least one biobased noxa, in particular of diseases comprising at least one barrier malfunction in at least one cell layer of at least one epithelial tissue, wherein at least one solute is selected from compounds of formula I, of formula II, physiologically compatible salts of formula I, formula II, stereoisomeric forms of the compounds of formula I, formula II, and physiologically compatible salts of the stereoisomeric forms, or a mixture of at least two of the afore-mentioned compounds. The at least one compatible solute, solute mixture and/or the compositions are provided in the form of a cosmetic, medical product, medicament, of an additive to one of the afore-mentioned products or as component of an in-vitro diagnostic product (IVD).

Claim (Index 36):
The method of  claim 23 , wherein the epithelial tissue barrier malfunction is associated with a disease of an outer epithelial tissue and/or a transitional epithelial tissue selected from the group consisting of:\n outer epithelial tissue diseases selected from the group consisting of diseases of the skin and the subcutis, infections of the skin and/or of the subcutis, mycoses, dry skin, contact allergies, dermatitis, eczema, neurodermatitis, psoriasis, urticaria, herpes, orofacial herpes, diseases of the eye, conjunctivitis, keratitis, diseases of the outer ear, inflammation of the outer ear, inflammation of the outer auditory canal, Otitis externa, and physical impairment of and/or damage to the skin structure comprising injuries, stings, slashes, scratches, abrasions, burns and/or chemical burns, each triggered by at least one biobased noxa; and transitional epithelial tissue diseases selected from the group consisting of allergic reaction of the nasal mucosa, allergic reactions of at least one mucosa of the oral cavity, dry nasal mucosa, diseases of the oral cavity, cysts, phlegmons, and/or abscesses of the oral mucosa, allergic lesions of the oral mucosa and/or of the tongue, diseases of the upper respiratory tract, nasal sinusitis, allergic rhinitis, allergic rhinopathy, tonsillitis, inflammations and infections of the mucosa of mouth, gingiva, tongue, throat, nose and/or genitals.

Metadata:
- Claim Count in Document: 53.0
- Percentile: 94.0
- Lexical Diversity: 2.45833
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['12675264', '15963493', '13042958', '12604609', '14317079']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6391584829128014
- 35 USC 102 Novelty (BERT): 0.5077382544812539
- Combined Prediction Score: 0.6260164600696466
- Mean Citation Score: 169.041678
- Max Citation Score: 186.14357
- Similarity Product: 109.98554594294906

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test